APOC3

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Retrieved on: 
Sunday, April 7, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Arrowhead, Principal, Urinary tract infection, JAMA Cardiology, Apolipoprotein C-III, Risk, Headache, Patient, Hypertriglyceridemia, Diarrhea, COVID-19, American College, APOC3, Pancreatitis, Safety, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).
  • Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels.
  • These data were presented in a late-breaking oral presentation today at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta and simultaneously published in the journal JAMA Cardiology .
  • Subjects treated with plozasiran also showed improvements in multiple atherogenic lipid and lipoprotein levels, including remnant cholesterol, HDL-cholesterol, and non-HDL cholesterol.

Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results

Retrieved on: 
Wednesday, November 29, 2023
Oncology, Health, Genetics, General Health, Pharmaceutical, Cardiology, Biotechnology, Webcast, Hypertriglyceridemia, GLP, Johnson & Johnson, Janssen Pharmaceuticals, Toxicology, International, RNA interference, Heart, AHA, GSK plc, Cholesterol, PIN, ERS, Patient, Cleveland Clinic, European Respiratory Society, Idiopathic pulmonary fibrosis, American Heart Association, GSK, MD, Janssen, Doctor of Philosophy, ANGPTL3, Triglyceride, Pharmaceutical industry, Medical device, Arrowhead, Medicine, APOC3

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023.
  • The company is hosting a conference call today, November 29, 2023, at 4:30 p.m.
  • ET to discuss the results.
  • JNJ-3989 (formerly ARO-HBV) was initially in-licensed by Janssen from Arrowhead in 2018

Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, MTV: TRL Christmas, Malignancy, Safety, Fasting, Heart, Risk, AHA, Hypertriglyceridemia, TGS, Apolipoprotein B, Serum, Cleveland Clinic, Baylor College of Medicine, APOC3, American Heart Association, Dyslipidemia, MD, Triglyceride, Doctor of Philosophy, ASCVD, Arrowhead Pharmaceuticals, ANGPTL3, Moyamoya disease, Pharmaceutical industry, Shipbuilding, Medical device, Arrowhead, Medicine, Patient

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) at the American Heart Association (AHA) Scientific Sessions 2023, being held in Philadelphia, PA, on November 11-13, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) at the American Heart Association (AHA) Scientific Sessions 2023, being held in Philadelphia, PA, on November 11-13, 2023.
  • Despite potent LDL-C lowering therapies, residual ASCVD risk persists due in part to high levels of atherogenic TRLs.
  • At 24 weeks, plozasiran durably decreased serum APOC3 to -79%, TGs to -74%, and remnant cholesterol to -63%, while increasing HDL-cholesterol to +68%.
  • Serious TEAEs were not related to plozasiran and were resolved without sequelae, except two subjects with malignancies.

Arrowhead Receives FDA Fast Track Designation for ARO-APOC3

Retrieved on: 
Monday, March 20, 2023
FDA, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Arrowhead, Hypertriglyceridemia, Triglyceride, NDA, Fast Track, Merrell Dow Pharmaceuticals Inc. v. Thompson, Trial of the century, Orphan drug, PALISADE, Genetic disorder, Arrowhead Pharmaceuticals, MD, Patient, European, APOC3, RNA interference, FCS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS).
  • ARO-APOC3 was previously granted Orphan Drug designation by the FDA and the European Union.
  • Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fulfill an unmet medical need.
  • This designation makes Arrowhead eligible for multiple potential benefits including more frequent interactions with FDA, eligibility for accelerated approval and priority review, and rolling review of the new drug application (NDA).

Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results

Retrieved on: 
Monday, February 6, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Molecule, Moyamoya disease, Trial of the century, NEJM, AHA, SEQUOIA, FCS, PIN, Safety, High-density lipoprotein, Outline, American Heart Association, Patient, Webcast, APOC3, MMP7, Sale, The New England Journal of Medicine, Therapy, Gout, IPF, Takeda, Liver disease, Triglyceride, RNA interference, Idiopathic pulmonary fibrosis, Horizon Therapeutics, Cardiovascular disease, Pharmacokinetics, Hypertriglyceridemia, Arrowhead, Cryptocurrency, Pharmaceutical industry, Amgen

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022.
  • The company is hosting a conference call today, February 6, 2023, at 4:30 p.m.
  • ET to discuss the results.
  • Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.

Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results

Retrieved on: 
Monday, November 28, 2022
Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, Other Science, Molecule, Arrowhead, American Heart Association, AHA, APOC3, MMP7, PIN, The New England Journal of Medicine, Triglyceride, RNA interference, NEJM, Hypertriglyceridemia, Patient, Cardiovascular disease, Moyamoya disease, Lipoprotein(a), Webcast, FCS, Sale, IPF, Royalty Pharma, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Amgen

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022.
  • The company is hosting a conference call today, November 28, 2022, at 4:30 p.m.
  • ET to discuss the results.
  • Presented interim data on the cardiometabolic pipeline in three late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2022 and at a virtual analyst and investor event.

Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline

Retrieved on: 
Monday, November 7, 2022
Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Molecule, TGS, Investor, NASDAQ, News, ANGPTL3, Private Securities Litigation Reform Act, Arrowhead Pharmaceuticals, U.S. Securities and Exchange Commission, The New England Journal of Medicine, Patient, Company, American Heart Association, Mount Sinai, FCS, Population, Mission statement, Baylor College of Medicine, Diet, Trial of the century, Baylor University, RNA, Gene, Icahn School of Medicine at Mount Sinai, HTG, Drug development, COVID-19, Arrowhead, APOC3, Amgen, Cardiovascular disease, Pain, AHA, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., History, Hypertriglyceridemia, Moyamoya disease, Gene silencing, Fasting, Liver disease, Annual report, Therapy, Risk, Lipoprotein lipase, Safety, Security (finance), Lipid, Pharmaceutical industry, RNA interference, Medicine

These data were presented during the Nov. 6 Late-Breaking Science Session and simultaneously published in the New England Journal of Medicine .

Key Points: 
  • These data were presented during the Nov. 6 Late-Breaking Science Session and simultaneously published in the New England Journal of Medicine .
  • The November 9, 2022 analyst and investor event will feature presentations from key opinion leaders, Christie M. Ballantyne, M.D.
  • This interim analysis (data cutoff July 6, 2022) evaluated data when all subjects reached week 12.
  • This interim analysis (data cutoff July 25, 2022) evaluated data when greater than 50% of subjects had reached week 12 and received both doses.

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3

Retrieved on: 
Tuesday, October 11, 2022
Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, News, U.S. Securities and Exchange Commission, Cardiovascular disease, Risk, Therapy, Investor, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Annual report, NASDAQ, Arrowhead, Arrowhead Pharmaceuticals, Lipid, Hypertriglyceridemia, AHA, RNA, Twitter, Baylor University, APOC3, Security (finance), HTG, Private Securities Litigation Reform Act, RNA interference, Trial of the century, Mission statement, Company, Lipoprotein lipase, Liver disease, Fasting, FCS, American Heart Association, Safety, Diet, TGS, Gene silencing, Icahn School of Medicine at Mount Sinai, Baylor College of Medicine, COVID-19, Gene, ANGPTL3, Mount Sinai, Pharmaceutical industry, Medicine, Cholesterol, Patient, Triglyceride

The company will also host a virtual analyst and investor event on November 9, 2022, at 10:00 am ET to discuss these data and Arrowheads plans for future clinical development.

Key Points: 
  • The company will also host a virtual analyst and investor event on November 9, 2022, at 10:00 am ET to discuss these data and Arrowheads plans for future clinical development.
  • In the Phase 2 ARCHES-2 clinical study ( NCT04832971 ), eligible subjects (n=203) were randomized 3:1 to receive subcutaneous injections of 50, 100, or 200 mg ARO-ANG3 or placebo on day 1 and at week 12.
  • This interim analysis (data cutoff July 6, 2022) evaluated data when all subjects reached week 12.
  • This interim analysis (data cutoff July 25, 2022) evaluated data when greater than 50% of subjects had reached week 12 and received both doses.

Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results

Retrieved on: 
Tuesday, May 10, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Completeness, ANGPTL3, NASDAQ, RNA, Company, Safety, Patient, Trial of the century, APOC3, Webcast, Apolipoprotein C-III, RNA interference, PNH, Adult, Conference, PALISADE, Paroxysmal nocturnal hemoglobinuria, Pharmaceutical industry, Vaccine

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2022.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2022.
  • The company is hosting a conference call today, May 10, 2022, at 4:30 p.m.
  • For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 3791265.
  • An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days.

Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results

Retrieved on: 
Wednesday, February 2, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Webcast, APOC3, Safety, American Association, Patient, NASDAQ, Janssen Pharmaceuticals, Trial of the century, Apolipoprotein C-III, NASH, Johnson & Johnson, Annual general meeting, AASLD, PALISADE, CTAS, GSK, Company, RNA interference, Association, Fatty liver disease, CTA, Foot, Conference, RNA, Liver disease, GlaxoSmithKline, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2021.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2021.
  • The company is hosting a conference call today, February 2, 2022, at 4:30 p.m.
  • ET to discuss the results.
  • For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 9844328.